Packaging can reveal a discrepancy, but chemical identity, amount and microbiological quality require different evidence.
A photograph can show an unusual cap, a copied logo or an inconsistent lot number. It cannot show the full chemical composition of a vial. When a counterfeit concern appears online, that distinction matters: visible packaging is evidence about packaging, while conclusions about identity, content and contamination require additional evidence.
An attractive label is not proof of authenticity. An unattractive one is not proof that the contents are counterfeit. The productive question is which observation supports which conclusion, and what would be needed to resolve the next question. This article explains that evidence sequence without judging any particular seller from photographs.
Separate three questions that often get combined
First is provenance: who made, supplied and handled the item, and can that history be supported? Second is chemical characterization: what material is present, in what form and amount, within the limits of the methods used? Third is suitability for the intended use, including microbiological questions where relevant.
These questions overlap operationally but are not interchangeable. A provenance discrepancy can justify investigation without identifying the chemical contents. A chemical result can characterize a submitted sample without establishing its entire distribution history. A single purity result also cannot answer every question about microorganisms or endotoxins.
As a practical review framework, keep the observations in separate fields. Record “label differs from the reference image,” “document issuer confirmed this report,” and “sample tested by the stated method” as different findings. Combining them into an undifferentiated “verified” badge makes the conclusion harder to audit.
| Evidence | Can help establish | Does not establish alone |
|---|---|---|
| Packaging photograph | Visible identifiers | Chemical contents |
| Supply records | Documented provenance | Every quality attribute |
| Analytical report | Defined sample results | Entire supply history |
| QR destination | Linked information | Authenticity by itself |
An authentic lot number can be copied
FDA's December 5, 2025 counterfeit-Ozempic update illustrates the problem precisely. The counterfeit items carried PAR1229, which was also an authentic lot number. FDA described a specific difference in EXP/LOT-text placement and identified genuine units supplied through the manufacturer's Patient Assistance Program.[1]
The lesson is not that lot numbers are useless. They are important traceability identifiers. The lesson is that an identifier printed on an object is a claim that must be connected to trustworthy records. A copied valid number does not automatically connect the object to the genuine batch.
The alert's visual markers were meaningful for the specified counterfeit presentation. They do not create a universal rule about cap colors, vial shapes, fonts or powder appearance. A laboratory reagent in a different container requires its own evidence. Extending an official product-specific comparison to every research vial would lose the very specificity that made the alert useful.
Read a QR code as a link, not a laboratory result
A QR code can make documentation easier to find. The useful follow-up is to inspect the destination, identify the issuer, match the product and lot, and confirm which report version is current. A link to a certificate is a route to evidence; it is not the evidence's independent authentication.
Even a genuine report needs sample linkage. Which vial or submitted sample was examined? Who sampled it? Does the report identify a lot, a sample identifier or merely a product name? Was the result generated before or after a relevant change in handling? These are proposed review questions, not accusations that any document is false.
When authenticity of a report matters, contact the issuing laboratory through a channel established independently of the questionable document. Our article on checking a COA with the issuing laboratory explains that process. A favorable issuer response still needs to be matched to the supplied material and the report's actual scope.
Chemical identity and quantity need defined methods
An appearance observation cannot identify a sequence, salt form or impurity profile. Neither does a nominal amount on the label establish the measured amount in the vial. Those are analytical questions with method-specific limits. The proposed test must be selected for the attribute being investigated rather than for how reassuring its name sounds.
Bachem's technical FAQ distinguishes gross weight, net peptide content and the information reported by its analytical methods.[3] That distinction is relevant here because packaging may display an amount without explaining its basis. A result about chromatographic purity and a result about material content should not be merged simply because both use a percentage.
For a suspected substitution, the right question is what evidence can discriminate the plausible identities. For a content concern, it is how the amount was calibrated and reported. For an impurity concern, it is what the method can separate or detect. These are conceptual investigation paths, not a claim that Chudik Scientific has performed those examinations or offers every technique.
Keep sterility and harm claims precise
FDA's earlier counterfeit-Ozempic investigation reported counterfeit needles and said their sterility could not be confirmed.[1] That is a significant uncertainty. It should not be rewritten as proof that every needle failed a sterility test, or that all counterfeit products have the same measured contamination.
The December 2025 update provides another caution about interpretation: six adverse events associated with the named lot involved authentic product, and none appeared associated with the counterfeit items.[1] A summary that attributes those events to the counterfeit units would be inaccurate. The article can describe a serious authenticity concern while preserving what the agency did and did not connect to harm.
FDA separately discusses fraudulent labeling and other concerns involving unapproved GLP-1 products.[2] That broader warning does not chemically identify an individual vial shown in a photograph. An official alert, a visual discrepancy and a sample-specific laboratory result remain different kinds of evidence.
Document the concern without inventing the conclusion
A useful record contains the original images, acquisition details, supplier and catalog identifiers, lot text, relevant documents and the exact discrepancy. Preserve the distinction between a suspicion, an issuer-confirmed inconsistency and a measured result. This makes it possible to communicate clearly without presenting an untested allegation as an established fact.
If the concern involves a medicine, use the relevant official alert and appropriate health professional or authorized supply-chain contact. Research-use materials should not be treated as ready for personal administration based on packaging or a certificate. A polished presentation does not bridge that gap.
This article draws on dated FDA alerts and a manufacturer's technical explanation of analytical reporting. It does not authenticate any current package, assess an individual supplier or report original testing. Its purpose is to help readers ask for evidence that actually answers their concern.